Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers

被引：3

|

作者：

Weir, MR ^{[1
]}

机构：

[1] Univ Maryland Hosp, Div Renal, Baltimore, MD 21202 USA

来源：

CURRENT HYPERTENSION REPORTS | 2002年 / 4卷 / 05期

关键词：

D O I：

10.1007/s11906-002-0059-5

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

引用

收藏

页码：333 / 335

页数：3

相关论文

共 50 条

[41] Claims in advertising of Angiotensin II Receptor Blockers
Greving, JP
Denig, P
Haaijer-Ruskamp, FM
de Zeeuw, D
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (04) : 478 - 479
[42] Effects of angiotensin II type 1 receptor blockers on the parameters of cardiovascular risk in hypertensive patients with type 2 diabetes
Ozaki, Nobuaki
Nomura, Yoshio
Sobajima, Hiroshi
Kondo, Kunikazu
Oiso, Yutaka
DIABETES, 2008, 57 : A615 - A616
[43] New definitions in cardiovascular risk management: is it time for angiotensin II receptor blockers to become first-line medication?
Jennings, G
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2003, 5 (0F) : F3 - F11
[44] Angiotensin II receptor blockers and insulin resistance
Ciccarelli, Leonardina
HYPERTENSION RESEARCH, 2010, 33 (08) : 779 - 779
[45] Effects of angiotensin II receptor blockers on dementia
Masaki Mogi
Masatsugu Horiuchi
Hypertension Research, 2009, 32 : 738 - 740
[46] Angiotensin II receptor blockers and insulin resistance
Leonardina Ciccarelli
Hypertension Research, 2010, 33 : 779 - 779
[47] Angiotensin II type 1 receptor blockers
Burnier, M
CIRCULATION, 2001, 103 (06) : 904 - 912
[48] ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS
Luan, L.
Hu, H.
Li, S. S.
VALUE IN HEALTH, 2018, 21 : S35 - S35
[49] Angiotensin II receptor blockers in heart failure
Patterson, JH
PHARMACOTHERAPY, 2003, 23 (02): : 173 - 182
[50] Angiotensin II receptor blockers and nephropathy trials
Bloomgarden, ZT
DIABETES CARE, 2001, 24 (10) : 1834 - 1838

← 1 2 3 4 5 →